Member Info for crumbs

I thought it was patients on it who were not having a good immune response to it....

Has definitely hit SCIB1 combo and nothing to do with the science or Yellowstone blowing... should scancell have been smarter?.... To me though I want patients to benefit and the trial is on (kinda) now.... it seems we would have been better leaving ImmunoBody to CRUK nano delivered funded by them SCIB2 combo now... whenever that happens!
Too much has been spent and lost on it when we have modi1 trial to concentrate on .... Anyways I hope more of a coherent plan emerges but seems a lot hangs on a glycan MaBs deal.... interest in that from the industry has been since at least 2015 yet as with all platforms still no commercial action...

Think that depends on if steve made it or not...

The thing is.... the patients scancell are recruiting ought to already be on Keytruda so I do not get the issue of payment for it??? they are already on it!

Yes, this combo trial is becoming an albatross .... I thought it was already agreed about the CI and that is why they decided to run a UK arm hmmm

I have a feeling a lot of work has already gone on with this involving the 2 interested companies who Lindy talked of in 2015... Avidimab might be new to scancell but it is not new to Lindy .... the part-timer brought her work home :)

What no biscuits!!!?

Thanks bob I thought you would have gone... did you get to mine anything in the tea and biscuits chats?...

They'll be a few more rounds

the phrase 'DYOR before investing ' comes to mind... they did and they did

He probably read 6 years of BB posts as part of the due diligence

That'll do for starters :)

They are all diving on the biscuits

It is mainly a US connected thing I think...So BioNtech wanting to list on NASDAQ could be a reason... the idea was the falling out with the US should mean more Chinese Bio investment elsewhere especially Europe....

I suppose the pioneers of manned rockets needed a certain breed of man to get inside them :) me I would want to be ground crew only

lol I hope Yellowstone blowing is factored in :)
All I'm saying is yes scientifically it all should go fine though it is a trial for a reason and not yet approved ... so until then there is risk and the danger of the unforeseen....

Not every patient in the first SCIB1 trial had a positive outcome.... despite the fact that SCIB1 seemed to have caused an immune response in everyone that got a therapeutic dose.... we just need to get that data in ... like I say I'm confident it will produce strong data... I would be more surprised if it did not than if it did but I accept there is that possibility...which I suppose is where you differ

I would be surprised if this trial does not give some positive and hopefully very positive data for all those reasons of synergy and that SCIB1 has indeed already got validating data in human trial....

however there is always the unforeseen element ... so until the data is in it is impossible to say there is no risk.... you can get in a car and go on a journey but until you arrive safely at your destination you cannot say it is impossible that you will suffer a crash

The possible mechanism of failure is.... the unforeseen :)

I think inananco mentioned it.... anyways on that note here is a really worthy read about Abbies blockbuster MaB humira and how they keep it from going over the patent cliff :)
'How was the company able to rack up so many patents on a single product? Much of it has to do with the type of drug that Humira is—a “biologic.” Unlike chemically synthesized drugs, biologics derive from actual biological material, making them significantly more complex than standard chemical medicines. And therein lies the key to AbbVie’s IP strategy, explains Feldman. For instance, a company may be able to file patents on obscure steps in the production and manufacturing process, or adjustments in dosing. '

And that’s precisely what AbbVie has done. AbbVie, in an emailed statement, says the U.S. Patent and Trademark Office (USPTO) has granted the company more than 30 patents on the ways in which the drug is administered; more than 25 patents on various formulations of the drug; more than 50 patents related to Humira’s manufacturing processes; and about 20 patents on the delivery devices that customers use to take the medicine.

To be sure, creating a monoclonal antibody isn’t easy work, explains Goodwin Procter attorney Robert Cerwinski. “The manufacture of adalimumab [Humira’s scientific name] occurs through a process called fermentation, and it involves a cell line that’s genetically engineered to secrete large amounts of adalimumab from a huge vat of cells growing in, like, a 15,000-liter bioreactor,” he tells Fortune.

Then things get even more complicated. Afterward, the treatment must go through purification processes to take out unnecessary by-products, modifications in dosage for different diseases, and all sorts of incremental tweaks. Amid all these procedures, Cerwinski says, “branded product sponsors like ­AbbVie have found many more opportunities to conclude that little wrinkles in the manufacturing process are innovative and can be protected by patents.”
https://fortune.com/longform/abbvie-humira-drug-costs-innovation/

Another link
https://gtr.ukri.org/project/40E94A75-28A8-478D-9CB0-D2C785BDAC3B